natgillin/translations-raw huggingface dataset:
Concomitant administration of atovaquone/proguanil with Atripla should be avoided whenever possible.
Istovremenu primjenu atovakona/progvanila s Atriplom treba izbjegavati kad god je to moguće.
Concomitant administration of atovaquone/proguanil with efavirenz should be avoided whenever possible.
Istovremenu primjenu atovakvona/progvanila s efavirenzom treba izbjegavati uvijek kad je to moguće.
Concomitant administration of boosted PREZISTA and these glucocorticoids is not recommended unless the potential benefit of treatment outweighs the risk of systemic corticosteroid effects.
Istodobna primjena pojačane PREZISTE i ovih glukokortikosteroida nije preporučena osim u slučajevima kada potencijalna korist liječenja nadilazi rizik sistemskih učinaka glukokortikosteroida.
Concomitant administration of boosted PREZISTA with ticagrelor is contraindicated.
Istodobna primjena pojačane PREZISTE s tikagrelorom je kontraindicirana.
Concomitant administration of EMEND with active substances that inhibit CYP3A4 activity (e.g., ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, telithromycin, nefazodone, and protease inhibitors) should be approached cautiously, as the combination is expected to result in several-fold increased plasma concentrations of aprepitant (see section 4.4).
Treba pozorno razmotriti istodobnu primjenu lijeka EMEND i djelatnih tvari koje inhibiraju aktivnost CYP3A4 (npr. ketokonazola, itrakonazola, vorikonazola, posakonazola, klaritromicina, telitromicina, nefazodona i inhibitora proteaze) jer se očekuje da bi takva kombinacija mogla višestruko povisiti koncentraciju aprepitanta u plazmi (vidjeti dio 4.4).
Concomitant administration of EMEND with active substances that inhibit CYP3A4 activity (e.g., ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, telithromycin, nefazodone, and protease inhibitors) should be approached cautiously, as the combination is expected to result several-fold in increased plasma concentrations of aprepitant (see section 4.4).
Treba pozorno razmotriti istodobnu primjenu lijeka EMEND i djelatnih tvari koje inhibiraju aktivnost CYP3A4 (npr. ketokonazola, itrakonazola, vorikonazola, posakonazola, klaritromicina, telitromicina, nefazodona i inhibitora proteaze) jer se očekuje da bi takva kombinacija mogla višestruko povisiti koncentraciju aprepitanta u plazmi (vidjeti dio 4.4).
Concomitant administration of EMEND with herbal preparations containing St. John’s Wort (Hypericum perforatum) is not recommended.
Ne preporučuje se istodobna primjena lijeka EMEND i biljnih lijekova koji sadrže gospinu travu (Hypericum perforatum).
Concomitant administration of Enurev Breezhaler and orally inhaled indacaterol, a beta2-adrenergic agonist, under steady-state conditions of both active substances did not affect the pharmacokinetics of either medicinal product.
Istodobna primjena Enurev Breezhaler i oralno inhaliranog indakaterola, beta2-adrenergičkog agonista, u stanju dinamičke ravnoteže obje djelatne tvari nije utjecala na farmakokinetiku ni jednog ni drugog lijeka.
Concomitant administration of erythropoietic agents or previous history of DVT may also increase thrombotic risk in these patients.
Istodobna primjena eritropoetskih lijekova ili prethodna anamneza duboke venske tromboze može također povećati trombotski rizik u tih bolesnika.
Concomitant administration of esomeprazole and a combined inhibitor of CYP2C19 and CYP 3A4 may result in more than doubling of the esomeprazole exposure.
Istodobna primjena esomeprazola i kombiniranog inhibitora CYP2C19 i CYP3A4 može više nego dvostruko povećati izloženosti esomeprazolu.
Concomitant administration of esomeprazole and a CYP3A4 inhibitor, clarithromycin (500 mg twice a day (b.i.d.)), resulted in a doubling of the exposure (AUC) to esomeprazole.
Istodobna primjena esomeprazola i inhibitora CYP3A4, klaritomicina, (500 mg dvaput na dan), udvostručila je izloženost (AUC) esomeprazolu.
Concomitant administration of fibrates, statins, danazol, ciclosporin or potent cytochrome P450 (CYP) 3A4 inhibitors (see section 4.5)
Istodobna primjena fibrata, statina, danazola, ciklosporina ili potentnih inhibitora citokroma P450 (CYP) 3A4 (vidjeti dio 4.5)
Concomitant administration of food decreased the rate of absorption, but not the extent of absorption.
Istovremena primjena hrane smanjila je brzinu apsorpcije, ali ne i veličinu apsorpcije.
Concomitant administration of fosaprepitant with herbal preparations containing St. John’s Wort (Hypericum perforatum) is not recommended.
Ne preporučuje se istodobna primjena fosaprepitanta i biljnih lijekova koji sadrže gospinu travu (Hypericum perforatum).
Concomitant administration of gefitinib with ranitidine at a dose that caused sustained elevations in gastric pH ≥5 resulted in a reduced mean gefitinib AUC by 47% in healthy volunteers (see section 4.4 and 5.2).
Istodobna primjena gefitiniba s ranitidinom u dozi koja uzrokuje trajno povišenje želučanog pH ≥5, u zdravih je dobrovoljaca uzrokovala smanjenje prosječnog AUC-a gefitiniba za 47% (vidjeti dijelove 4.4 i 5.2).
Concomitant administration of inhibitors of Pgp, e.g. cyclosporine and verapamil, may lead to altered distribution and/or altered elimination of erlotinib.
Istovremena primjena Pgp inhibitora, npr. ciklosporina i verapamila, može dovesti do promjene raspodjele i/ili uklanjanja erlotiniba.
Concomitant administration of Invirase and quetiapine is contra- indicated as it may increase quetiapine-related toxicity.
Istodobna primjena lijeka Invirase i kvetiapina je kontraindicirana jer može povećati toksičnost povezanu s kvetiapinom.
Concomitant administration of IXIARO and inactivated hepatitis A vaccine was shown to be non-inferior to single vaccinations with regard to GMT of anti-JE virus neutralizing antibody and HAV antibody, and for seroconversion rates of both antibody types (Table 7).
Istodobna primjena cjepiva IXIARO i inaktiviranog cjepiva protiv hepatitisa A pokazala se neinferiornom u odnosu na zasebnu primjenu tih cjepiva, obzirom na geometrijsku sredinu titra (GMT) neutralizirajućih anti-JEV protutitijela i HAV protutijela i obzirom na stope serokonverzije oba tipa protutijela (Tablica 7).
Concomitant administration of IXIARO with inactivated hepatitis A vaccine and with inactivated rabies vaccine in two different schedules has been evaluated in clinical studies.
U kliničkim ispitivanjima procjenjivana je istodobna primjena cjepiva IXIARO s inaktiviranim cjepivom protiv hepatitisa A i s inaktiviranim cjepivom protiv bjesnoće prema dva različita rasporeda.
Concomitant administration of IXIARO with inactivated rabies vaccine (Rabipur):
Istodobna primjena cjepiva IXIARO s inaktiviranim cjepivom protiv bjesnoće (Rabipur):
Concomitant administration of IXIARO with other vaccines:
Istodobna primjena cjepiva IXIARO s drugim cjepivima:
Concomitant administration of Kaletra and alfuzosin is contra- indicated (see section 4.3) as alfuzosin-related toxicity, including hypotension, may be increased.
Istodobna primjena lijeka Kaletra i alfuzosina je kontraindicirana (vidjeti dio 4.3) jer može doći do povećanja toksičnosti povezane s alfuzosinom, uključujući hipotenziju.
Concomitant administration of Kaletra with fusidic acid is contra-indicated in dermatological indications due to the increased risk of adverse events related to fusidic acid, notably rhabdomyolysis (see section 4.3).
Istodobna primjena lijeka Kaletra s fusidatnom kiselinom je kontraindicirana kod dermatoloških indikacija zbog povećanog rizika od štetnih događaja povezanih s fusidatnom kiselinom, osobito rabdomiolize (vidjeti dio 4.3).
Concomitant administration of Ketek and colchicine is contraindicated in patients with renal and/or hepatic impairment (see section 4.3).
Istodobna primjena lijeka Ketek i kolhicina je kontraindicirana u bolesnika s oštećenjem bubrežne i/ili jetrene funkcije (vidjeti dio 4.3).
Concomitant administration of levetiracetam and methotrexate has been reported to decrease methotrexate clearance, resulting in increased/prolonged blood methotrexate concentration to potentially toxic levels.
Pri istodobnoj primjeni levetiracetama i metotreksata prijavljeno je smanjenje klirensa metotreksata, što uzrokuje povišenu/zadržanu koncentraciju metotreksata u krvi do potencijalno toksičnih razina.
Concomitant administration of lopinavir/ritonavir and alfuzosin is contra-indicated (see section 4.3) as alfuzosin-related toxicity, including hypotension, may be increased.
Istodobna primjena lopinavira/ritonavira i alfuzosina je kontraindicirana (vidjeti dio 4.3) jer može doći do povećanja toksičnosti povezane s alfuzosinom, uključujući hipotenziju.
Concomitant administration of memantine with the antispasmodic agents, dantrolene or baclofen, can modify their effects and a dose adjustment may be necessary.
Istodobna primjena memantina sa spazmoliticima, dantrolenom ili baklofenom može promijeniti njihov učinak te će možda biti potrebno prilagoditi dozu.
Concomitant administration of memantine with the antispasmodic agents, dantrolene or baclofen, can modify their effects and a dose adjustment may be necessary.
Istodobna primjena memantina sa spazmoliticima, dantrolenom ili baklofenom, može promijeniti njihov učinak te će možda biti potrebno prilagoditi dozu.
Concomitant administration of memantine with the antispasmodic medicinal products, dantrolene or baclofen, can modify their effects and a dose adjustment may be necessary.
Istodobna primjena memantina sa spazmoliticima, dantrolenom ili baklofenom može promijeniti njihov učinak te će možda biti potrebna prilagodba doze.
Concomitant administration of moderate CYP3A4 inhibitors (see sections 4.2 and 4.5).
Kod istovremene primjene umjerenih inhibitora CYP3A4 (vidjeti dijelove 4.2 i 4.5).
Concomitant administration of nelarabine in combination with adenosine deaminase inhibitors, such as pentostatin is not recommended.
Istodobna primjena nelarabina i inhibitora adenozin deaminaze, poput pentostatina,se ne preporučuje.
Concomitant administration of orally inhaled indacaterol and glycopyrronium, under steady-state conditions of both components, did not affect the pharmacokinetics of either component.
Istodobna primjena oralno inhaliranog indakaterola i glikopironija, u uvjetima stanja dinamičke ravnoteže obiju komponenti, nije utjecala na farmakokinetiku bilo koje od komponenti.
Concomitant administration of other sympathomimetic agents (alone or as part of combination therapy) may potentiate the adverse events of indacaterol (see section 4.4).
Istodobna primjena drugih simpatomimetičkih tvari (samih ili u kombiniranom liječenju) može potencirati nuspojave indakaterola (vidjeti dio 4.4).
Concomitant administration of other sympathomimetic medicinal products (alone or as part of combination therapy) may potentiate the adverse reactions of fluticasone furoate/vilanterol.
Istodobna primjena drugih simpatomimetičkih lijekova (samostalno ili u sklopu kombinirane terapije) može potencirati nuspojave flutikazonfuroata/vilanterola.
Concomitant administration of P-gp inducers (such as rifampicin, St. John`s wort (Hypericum perforatum), carbamazepine, or phenytoin) is expected to result in decreased dabigatran plasma concentrations, and should be avoided (see sections 4.5 and 5.2).
Smatra se da istodobna primjena induktora P-gp (poput rifampicina, gospine trave (Hypericum perforatum), karbamazepina, ili fenitoina) rezultira sniženim koncentracijama dabigatrana u plazmi te ju je potrebno izbjegavati (vidjeti dijelove 4.5 i 5.2).
Concomitant administration of P-gp inhibitors (see sections 4.2 and 4.5).
Kod istovremene primjene inhibitora P-gp (vidjeti dijelove 4.2 i 4.5).
Concomitant administration of P-gp inhibitors (such as amiodarone, verapamil, quinidine, ketoconazole, dronedarone, clarithromycin and ticagrelor) is expected to result in increased dabigatran plasma concentrations.
Smatra se da istodobna primjena P-gp inhibitora (poput amiodarona, verapamila, kinidina, ketokonazola, dronedarona, klaritromicina i tikagrelora) rezultira povećanim koncentracijama dabigatrana u plazmi.
Concomitant administration of P-gp inhibitors (such as amiodarone, verapamil, quinidine, ketoconazole, dronedarone, clarithromycin and ticagrelor) is expected to result in increased dabigatran plasma concentrations.
Smatra se da istodobna primjena P-gp inhibitora (poput amiodarona, verapamila, kinidina, ketokonazola, dronedarona, klaritromicina, i tikagrelora) rezultira povećanim koncentracijama dabigatrana u plazmi.
Concomitant administration of P-gp inhibitors (such as amiodarone, verapamil, quinidine, ketoconazole, dronedarone, clarithromycin and ticagrelor) is expected to result in increased dabigatran plasma concentrations.
Smatra se da istodobna primjena P-gp inhibitora (poput amiodarona, verapamila, kinidina, ketokonazola, dronedarona, klaritromicina, tikagrelora) rezultira povećanim koncentracijama dabigatrana u plazmi.
Concomitant administration of potent inducers of P-gp, glucuronidation, and/or CYP3A4 (e.g. rifampicin, rifabutin, carbamazepine, phenytoin or St John’s Wort [Hypericum perforatum]) may lead to suboptimal exposure to vemurafenib and should be avoided.
Istodobna primjena snažnih induktora P-glikoproteina, glukuronidacije ili CYP3A4 (npr. rifampicina, rifabutina, karbamazepina, fenitoina ili gospine trave [Hypericum perforatum]) može dovesti do suboptimalne izloženosti vemurafenibu i treba ju izbjegavati.
Concomitant administration of potent inducers of P-gp, glucuronidation, CYP3A4 (e.g. rifampicin, rifabutin, carbamazepine, phenytoin or St John’s Wort [hypericin]) should be avoided when possible (see section 4.5).
Istodobnu primjenu snažnih induktora P-glikoproteina, glukuronidacije ili CYP3A4 (npr. rifampicina, rifabutina, karbamazepina, fenitoina ili gospine trave [Hypericum perforatum]) potrebno je izbjegavati kad god je moguće (vidjeti dio 4.5).
Concomitant administration of Prevenar 13 and 23-valent pneumococcal polysaccharide vaccine has not been studied.
Istovremena primjena Prevenara 13 i 23-valentnog pneumokoknog polisaharidnog cjepiva nije ispitana.
Concomitant administration of PREZISTA co-administered with low dose ritonavir and these glucocorticoids is not recommended unless the potential benefit of treatment outweighs the risk of systemic corticosteroid effects.
Istodobna primjena lijeka PREZISTA istodobno primjenjenog s niskom dozom ritonavira i ovih glukokortikosteroida nije preporučena osim u slučajevima kada potencijalna korist liječenja nadilazi rizik sistemskih učinaka glukokortikosteroida.
Concomitant administration of PREZISTA with low dose ritonavir with ticagrelor is contraindicated.
Istodobna primjena PREZISTE s niskom dozom ritonavira s tikagrelorom je kontraindicirana.
Concomitant administration of RotaTeq and oral poliomyelitis vaccine (OPV) did not affect the immune response to the poliovirus antigens.
Istodobna primjena RotaTeq cjepiva i oralnog cjepiva protiv poliomijelitisa (OPV) nije utjecala na imunološki odgovor na antigene poliovirusa.
Concomitant administration of saxagliptin with the potent CYP3A4/5 inducer rifampicin, reduced Cmax and AUC of saxagliptin by 53% and 76%, respectively.
Istodobna primjena saksagliptina s potentnim induktorom CYP3A4/5, rifampicinom, smanjila je Cmax saksagliptina za 53%, a AUC za 76%.
Concomitant administration of Seebri Breezhaler and orally inhaled indacaterol, a beta2-adrenergic agonist, under steady-state conditions of both active substances did not affect the pharmacokinetics of either medicinal product.
Istodobna primjena Seebri Breezhaler i oralno inhaliranog indakaterola, beta2-adrenergičkog agonista, u stanju dinamičke ravnoteže obje djelatne tvari nije utjecala na farmakokinetiku ni jednog ni drugog lijeka.
Concomitant administration of strong CYP3A4 inhibitors (e.g. boceprevir, clarithromycin, cobicistat, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, voriconazole) and strong CYP3A4 inducers (e.g. carbamazepine, phenobarbital, phenytoin, rifampicin, St John’s wort (Hypericum perforatum) (see section 4.5).
Istovremena primjena jakih CYP3A4 inhibitora (npr. boceprevira, klaritromicina, kobicistata, indinavira, itrakonazola, ketokonazola, nefazodona, nelfinavira, posakonazola, ritonavira, sakvinavira, telaprevira, telitromicina, vorikonazola) i jakih CYP3A4 induktora (npr. karbamazepina, fenobarbitala, fenitoina, rifampicina, gospine trave (Hypericum perforatum) (vidjeti dio 4.5).
Concomitant administration of sunitinib with potent CYP3A4 inhibitors should be limited because of the possible increase in sunitinib plasma concentrations (see sections 4.2 and 4.5).
Istodobnu primjenu sunitiniba sa snažnim inhibitorima CYP3A4 treba ograničiti zbog mogućeg povećanja koncentracija sunitiniba u plazmi (vidjeti dijelove 4.2 i 4.5).
Concomitant administration of Tarceva with 300 mg ranitidine, an H2-receptor antagonist, decreased erlotinib exposure [AUC] and maximum concentrations [Cmax] by 33% and 54%, respectively.
Istovremena primjena lijeka Tarceva s 300 mg ranitidina, antagonsita H2 receptora, smanjuje izloženost erlotinibu [AUC] za 33% i vršne koncentracije [Cmax] za 54%.
Concomitant administration of the P-gp substrate dabigatran etexilate may result in increased dabigatran plasma concentrations.
Istovremena primjena P-gp supstrata dabigatran eteksilata može rezultirati povećanim koncentracijama dabigatrana u plazmi.
Concomitant administration of these medicinal products is not recommended.
Istodobna primjena ovih dvaju lijekova se ne preporučuje.
Concomitant administration of these medicinal products is not recommended.
Istodobna primjena tih dvaju lijekova se ne preporučuje.
Concomitant administration of these medicinal products is not recommended.
lijekova se ne preporučuje.
Concomitant administration of thiazide diuretics with substances that also have a blood pressure lowering effect (e.g. by reducing sympathetic central nervous system activity or direct vasodilatation) may potentiate orthostatic hypotension.
Istodobna primjena tiazidskih diuretika s lijekovima koji također imaju učinak sniženja krvnog tlaka (npr. smanjenjem aktivnosti simpatičkoga živčanog sustava ili direktnom vazodilatacijom) može potencirati ortostatsku hipotenziju.
Concomitant administration of ticagrelor increased the digoxin Cmax by 75% and AUC by 28%.
Istodobna primjena tikagrelora povećala je Cmax digoksina za 75% i AUC digoksina za 28%.
Concomitant administration of tigecycline and warfarin (25 mg single-dose) to healthy subjects resulted in a decrease in clearance of R-warfarin and S-warfarin by 40 % and 23 %, and an increase in AUC by 68 % and 29 %, respectively.
Istovremena primjena tigeciklina i varfarina (jednokratna doza od 25 mg) kod zdravih ispitanika dovela je do smanjenja klirensa R-varfarina za 40%, a S-varfarina za 23% te porasta AUC-a R- varfarina za 68% odnosno S-varfarina za 29%.
Concomitant administration of torasemide with other drugs metabolised by cytochrome P450 families 3A4 (e.g.: enalapril, buprenorphine, doxycycline, cyclosporine) and 2E1 (isoflurane, sevoflurane, theophylline) may decrease their clearance from the systemic circulation.
Istovremena primjena torasemida s drugim lijekovima koje metaboliziraju obitelji 3A4 (npr. enalapril, buprenorfin, doksiciklin, ciklosporin) i 2E1 (izofluran, sevofluran, teofilin) citokroma P450 može smanjiti njihovo izlučivanje iz sustavne cirkulacije.
Concomitant administration of Tovanor Breezhaler and orally inhaled indacaterol, a beta2-adrenergic agonist, under steady-state conditions of both active substances did not affect the pharmacokinetics of either medicinal product.
Istodobna primjena Tovanor Breezhaler i oralno inhaliranog indakaterola, beta2-adrenergičkog agonista, u stanju dinamičke ravnoteže obje djelatne tvari nije utjecala na farmakokinetiku ni jednog ni drugog lijeka.
Concomitant administration of yellow fever vaccine is contraindicated, due to the risk of fatal disease in immunocompromised patients (see section 4.3).
Istodobna primjena cjepiva protiv žute groznice kontraindicirana je zbog rizika od smrtonosne bolesti u imunokompromitiranih bolesnika (vidjeti dio 4.3)
Concomitant administration with colchicine, notably in patients with renal or hepatic impairment, should be avoided (see section 4.5).
Mora se izbjegavati istodobna primjena s kolhicinom, osobito kod bolesnika s oštećenjem jetre ili bubrega (vidjeti dio 4.5).
Concomitant administration with ergot alkaloid derivatives (such as ergotamine and dihydroergotamine) (see section 4.5).
Istodobna primjena derivata ergot alkaloida (kao što su ergotamin i dihidroergotamin) (vidjeti dio 4.5).
Concomitant administration with hypertonic saline was not permitted in these trials.
Istodobna primjena hipertonične fiziološke otopine nije bila dopuštena u tim ispitivanjima.
Concomitant administration with lenalidomide 10 mg/day increased the plasma exposure of digoxin (0.5 mg, single dose) by 14% with a 90% CI (confidence interval) [0.52%-28.2%].
Istodobna primjena s lenalidomidom u dozi od 10 mg/dan povećala je plazmatsku izloženost digoksinu (0,5 mg, pojedinačna doza) za 14% uz interval pouzdanosti od 90% [0,52%-28,2%].
Concomitant administration with medicinal products that prolong the QT interval and are CYP3A4 substrates, such as cisapride, pimozide, astemizole, terfenadine, dronedarone, saquinavir (see section 4.5).
Istodobna primjena lijekova koji produljuju QT-interval i koji su supstrati CYP3A4, kao što su cisaprid, pimozid, astemizol, terfenadin, dronedaron, sakvinavir (vidjeti dio 4.5).
Concomitant administration with St John’s wort is not recommended (see section 4.5).
Istodobna primjena s gospinom travom se ne preporučuje (vidjeti dio 4.5).
Concomitant administration with St. John’s Wort is however not recommended (see section 4.4).
Istodobna primjena s gospinom travom se, međutim, ne preporučuje (vidjeti dio 4.4).
Concomitant anti-Parkinson medicinal products were kept stable during the study.
Nastavljena je stabilna istodobna primjena lijekova protiv Parkinsonove bolesti.
Concomitant antibiotic coverage
Istodobna primjena antibiotika
Concomitant application of sunscreen, either before or after Kentera application, had no effect on the systemic exposure of oxybutynin.
Istodobna primjena sunčane zaštite, prije ili nakon primjene Kentere, nije imala učinka na sistemsku ekspoziciju oksibutininu.
Concomitant asymptomatic cartilage lesions (ICRS grade I or II) might be present.
Mogu se pojaviti popratne asimptomatične lezije hrskavice (stupnja I ili II prema ICRS).
Concomitant consumption of grapefruit juice while taking naloxegol should generally be avoided and considered only in consultation with a healthcare provider (see section 4.3).
Istodobnu konzumaciju soka od grejpa tijekom liječenja naloksegolom u načelu se mora izbjegavati te razmotriti samo u dogovoru sa zdravstvenim djelatnikom (vidjeti dio 4.3).
Concomitant drug class:
Klasa istodobno primijenjenog lijeka:
Concomitant heparin use
Istovremena primjena heparina
Concomitant HIV therapy: PI-based
Istodobna terapija za HIV: utemeljena na PI
Concomitant hypokalaemic treatment with methylxanthine derivatives, steroids, or non-potassium- sparing diuretics may potentiate the possible hypokalaemic effect of beta2-adrenergic agonists, therefore caution is required (see section 4.4).
Istodobno liječenje lijekovima koji mogu uzrokovati hipokalijemiju, tj. derivatima metilksantina, steroidima ili diureticima koji ne štede kalij može potencirati mogući hipokalijemički učinak beta2- adrenergičkih agonista, pa je zato potreban oprez (vidjeti dio 4.4).
Concomitant hypokalaemic treatment with methylxanthine derivatives, steroids, or non-potassium- sparing diuretics may potentiate the possible hypokalaemic effect of beta2-adrenergic agonists, therefore use with caution (see section 4.4).
Istodobno hipokalijemičko liječenje derivatima metilksantina, steroidima ili diureticima koji ne štede kalij može potencirati mogući hipokalijemički učinak beta2-adrenergičkih agonista, pa ih zato treba primjenjivati s oprezom (vidjeti dio 4.4).
Concomitant illness, especially infections and feverish conditions, usually increases the patient’s insulin requirement.
Popratne bolesti, posebice infekcije i stanja praćena vrućicom, obično povećavaju bolesnikovu potrebu za inzulinom.